NanoPass Technologies is a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions and is currently sold throughout the world, from vaccines to aesthetics. NanoPass's IP-backed product, the MicronJet (registered with the US FDA, the EU, Brazil, China, Australia and other countries), is the most advanced hollow microneedles device available today. Its excellent performance is backed by more than 50 clinical studies. The Company has concluded the world's first intradermal pandemic flu vaccine study and additional seasonal flu studies, demonstrating equivalent or superior immunogenicity to standard delivery using only 20% of the dose. The company is backed by prominent Israeli and US investors ýand medical device companies, including IHCV, Ofer Hi-Tech, D-Partners, WFD Ventures and Elcam Medical. NanoPass recently closed a new round of financing, led by Israel Health Care Ventures (IHCV) NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.